The U.S. Food and Drug Administration (FDA) has alerted health care providers to rare but severe neurologic complications reported after general anesthesia, including cases involving the widely used anesthetic sevoflurane. The agency said it is investigating published reports of catastrophic outcomes, including permanent brain injury and death, in both adults and children who appeared to have an underlying genetic susceptibility.
In a safety communication published on its website, the FDA urged clinicians to be aware of the emerging signal and to report suspected cases, while emphasizing that general anesthesia remains a critical tool for surgery and other procedures.
What the FDA is Investigating
According to the FDA notice, the agency is reviewing scientific case reports describing patients who developed unexpected, severe neurologic damage after receiving general anesthesia. The reports involve sevoflurane and potentially other inhaled anesthetics, which are drugs administered as gases to keep patients unconscious during operations.
The FDA said the affected patients experienced catastrophic outcomes that were out of proportion to the procedures they underwent. In some cases, individuals who were previously healthy developed profound neurologic impairment or died following anesthesia. The agency’s communication links these events to suspected genetic factors that may alter how a patient’s brain or nervous system responds to these drugs.
The alert does not state how many cases have been identified or provide detailed patient-level data, but it describes the events as rare and unexpected. The FDA is treating the signal as serious enough to warrant direct communication with anesthesiologists, surgeons, and other clinicians who order or administer general anesthesia.
Possible Genetic Link and Known Risk Factors
The FDA’s message centers on the possibility that certain inherited traits may increase vulnerability to neurologic injury from general anesthetics such as sevoflurane. The agency bases this on published scientific reports, which describe patients with suspected or confirmed genetic variants who suffered severe brain-related complications after anesthesia.
The communication notes that these cases appear distinct from better-known anesthesia-related genetic conditions, such as malignant hyperthermia, a life-threatening reaction to certain anesthetic agents. Instead, the reports suggest a different pattern of injury, involving profound neurologic damage without the classic signs of malignant hyperthermia.
The FDA has not yet identified a specific gene or set of genes that clearly explains the cases under review. Rather, the agency characterizes the genetic connection as a working hypothesis drawn from the scientific literature. It is using the alert to signal that more investigation is needed and to encourage clinicians to consider possible genetic factors when evaluating unexplained neurologic outcomes after anesthesia.
Implications for Patients and Clinicians
In its notice, the FDA stresses that general anesthesia, including sevoflurane, is essential for modern surgery and that the overall safety record of these drugs is strong. The agency does not advise canceling necessary procedures or broadly avoiding sevoflurane or related agents.
Instead, the alert asks health care providers to:
- Be aware of the reported cases of severe neurologic complications following general anesthesia in patients with suspected genetic susceptibility.
- Review anesthesia plans carefully for patients with personal or family histories of unexplained neurologic injury after surgery.
- Monitor patients closely during and after anesthesia, especially when risk factors are present.
- Report any similar adverse events to the FDA’s MedWatch program, including details that might help identify genetic or other predisposing factors.
The FDA communication is aimed at anesthesiologists, surgeons, pediatric specialists, and other clinicians who may encounter such cases. The agency frames the alert as an early safety signal rather than a definitive conclusion about causality.
For patients, the FDA’s message implies that routine surgeries and procedures requiring anesthesia should generally continue as planned, but that individuals with a personal or family history of unexplained severe reactions to anesthesia may wish to discuss those details with their care team before undergoing another procedure.
How Regulators Are Responding
The FDA states that it is actively evaluating the available evidence, which currently consists primarily of published case reports and scientific analyses. These reports describe neurologic outcomes that were not anticipated based on the procedures performed or the patients’ prior health.
Regulators are reviewing:
- The specific anesthetic drugs used, including sevoflurane and any other general anesthetics administered.
- The timing and nature of neurologic symptoms after anesthesia.
- Any documented or suspected genetic findings in affected patients.
- Other potential contributing factors, such as underlying medical conditions or concurrent medications.
The agency has not announced any immediate changes to drug labeling or formal restrictions on sevoflurane or other anesthetics. Instead, it is using the safety communication to increase awareness while it continues to assess whether regulatory action is warranted.
The FDA also encourages researchers and clinicians who have encountered similar cases to publish their findings or report them directly to the agency. Additional case descriptions, the notice suggests, could help clarify whether a consistent pattern exists and which patients may be at highest risk.
Why This Matters Now
Sevoflurane is one of the most commonly used inhaled anesthetics in operating rooms and procedure suites in the United States. Because it is used so widely, even very rare complications can affect real patients and families.
The FDA’s alert matters for several reasons, based on the agency’s own description:
- It flags a potential, genetically linked risk of catastrophic neurologic injury in a setting that is otherwise tightly controlled and closely monitored.
- It signals that regulators see enough concern in the published literature to notify front-line clinicians before a full risk assessment is complete.
- It underscores the importance of detailed adverse-event reporting, including genetic information when available, to help determine whether a true safety signal exists.
For now, the FDA’s communication indicates that general anesthesia remains a standard and necessary part of medical care, but that clinicians should stay attentive to emerging evidence. The agency has said it will update the public and health care providers if its ongoing review identifies clearer risk factors or calls for changes in how sevoflurane and related anesthetics are used.
